CorMedix Announces Collaboration for DefenCath Promotion to the VA and Other Federal Facilities
CorMedix (Nasdaq: CRMD), a biopharmaceutical company, has announced a collaboration with WSI PBG, a subsidiary of Golden State Medical Supply, to promote DefenCath® to healthcare providers in facilities operated by the Department of Veterans Affairs (VA) and other federal facilities.
This partnership aims to enhance access to critical therapies for approximately 40,000 veterans living with end-stage renal disease (ESRD) and other beneficiaries of federal programs. WSI PBG will leverage its expertise in navigating VA and federal facilities, including access, procurement processes, and regulations, to meet the unique needs of these healthcare systems.
CorMedix and WSI PBG are committed to improving health outcomes by providing increased access to DefenCath for patients at VA and other federal facilities. Joe Todisco, CEO of CorMedix, expressed excitement about the collaboration, citing WSI PBG's deep understanding of the federal healthcare landscape as a key factor in enhancing access to DefenCath and ensuring equitable care for veterans and other federal healthcare beneficiaries.
CorMedix (Nasdaq: CRMD), un'azienda biofarmaceutica, ha annunciato una collaborazione con WSI PBG, una sussidiaria di Golden State Medical Supply, per promuovere DefenCath® presso i fornitori di assistenza sanitaria nelle strutture gestite dal Dipartimento degli Affari dei Veterani (VA) e in altre strutture federali.
Questa partnership mira a migliorare l'accesso a terapie cruciali per circa 40.000 veterani che vivono con malattia renale in fase terminale (ESRD) e per altri beneficiari di programmi federali. WSI PBG sfrutterà la sua esperienza nella navigazione delle strutture VA e federali, inclusi accesso, processi di approvvigionamento e normative, per soddisfare le esigenze uniche di questi sistemi sanitari.
CorMedix e WSI PBG sono impegnate a migliorare gli esiti sanitari fornendo un accesso maggiore a DefenCath per i pazienti nelle strutture VA e altre strutture federali. Joe Todisco, CEO di CorMedix, ha espresso entusiasmo per questa collaborazione, citando la profonda comprensione di WSI PBG del panorama sanitario federale come un fattore chiave per migliorare l'accesso a DefenCath e garantire un'assistenza equa per i veterani e altri beneficiari di assistenza sanitaria federale.
CorMedix (Nasdaq: CRMD), una empresa biofarmacéutica, ha anunciado una colaboración con WSI PBG, una subsidiaria de Golden State Medical Supply, para promover DefenCath® ante los proveedores de atención médica en las instalaciones operadas por el Departamento de Asuntos de Veteranos (VA) y otras instalaciones federales.
Esta asociación tiene como objetivo mejorar el acceso a terapias críticas para aproximadamente 40,000 veteranos que viven con enfermedad renal en etapa terminal (ESRD) y otros beneficiarios de programas federales. WSI PBG aprovechará su experiencia en la navegación de instalaciones VA y federales, incluidos acceso, procesos de adquisición y regulaciones, para satisfacer las necesidades únicas de estos sistemas de salud.
CorMedix y WSI PBG están comprometidas a mejorar los resultados de salud al proporcionar un mayor acceso a DefenCath para pacientes en instalaciones VA y otras instalaciones federales. Joe Todisco, CEO de CorMedix, expresó su entusiasmo por la colaboración, citando la profunda comprensión de WSI PBG del panorama de atención médica federal como un factor clave para mejorar el acceso a DefenCath y garantizar atención equitativa para los veteranos y otros beneficiarios de atención médica federal.
CorMedix (Nasdaq: CRMD), 생명공학 제약회사, 는 Golden State Medical Supply의 자회사인 WSI PBG와 협력하여 DefenCath®를 재향군인부(VA) 및 기타 연방 시설에서 의료 제공자에게 홍보하겠다고 발표했습니다.
이 파트너십은 말기 신장 질환(ESRD)으로 고통받는 약 40,000명의 재향군인 및 기타 연방 프로그램 수혜자들에게 중요한 치료 접근을 개선하는 것을 목표로 합니다. WSI PBG는 이러한 의료 시스템의 고유한 요구를 충족하기 위해 VA 및 연방 시설 내 접근, 조달 과정 및 규정을 탐색하는 전문 지식을 활용할 것입니다.
CorMedix와 WSI PBG는 VA 및 기타 연방 시설의 환자들에게 DefenCath에 대한 접근성을 높임으로써 건강 결과를 개선하기 위해 헌신하고 있습니다. CorMedix의 CEO인 Joe Todisco는 이 협력을 통해 WSI PBG의 연방 의료 환경에 대한 깊은 이해가 DefenCath의 접근성을 증진하고 재향군인 및 기타 연방 의료 수혜자들에게 공평한 치료를 보장하는 중요한 요소가 될 것이라고 전했습니다.
CorMedix (Nasdaq: CRMD), une entreprise bio-pharmaceutique, a annoncé une collaboration avec WSI PBG, une filiale de Golden State Medical Supply, pour promouvoir DefenCath® auprès des fournisseurs de soins de santé dans les établissements gérés par le Département des Anciens Combattants (VA) et d'autres établissements fédéraux.
Ce partenariat vise à améliorer l'accès à des thérapies critiques pour environ 40.000 anciens combattants vivant avec une maladie rénale à un stade terminal (ESRD) et d'autres bénéficiaires de programmes fédéraux. WSI PBG s'appuiera sur son expertise en matière de navigation dans les établissements VA et fédéraux, notamment en ce qui concerne l'accès, les processus d'approvisionnement et la réglementation, pour répondre aux besoins uniques de ces systèmes de santé.
CorMedix et WSI PBG s'engagent à améliorer les résultats en matière de santé en fournissant un meilleur accès à DefenCath pour les patients dans les établissements VA et autres établissements fédéraux. Joe Todisco, PDG de CorMedix, a exprimé son enthousiasme à l'égard de la collaboration, soulignant que la compréhension approfondie de WSI PBG du paysage des soins de santé fédéraux est un facteur clé pour améliorer l'accès à DefenCath et garantir des soins équitables pour les anciens combattants et autres bénéficiaires des soins de santé fédéraux.
CorMedix (Nasdaq: CRMD), ein biopharmazeutisches Unternehmen, hat eine Zusammenarbeit mit WSI PBG, einer Tochtergesellschaft von Golden State Medical Supply, bekannt gegeben, um DefenCath® bei Gesundheitsdienstleistern in Einrichtungen des Veteranenministeriums (VA) und anderen Bundesbehörden zu fördern.
Diese Partnerschaft zielt darauf ab, den Zugang zu kritischen Therapien für etwa 40.000 Veteranen, die an terminaler Niereninsuffizienz (ESRD) leiden, und andere Empfänger von Bundesprogrammen zu verbessern. WSI PBG wird seine Expertise in der Navigation durch VA- und Bundeseinrichtungen, einschließlich Zugang, Beschaffungsprozesse und Vorschriften, nutzen, um den einzigartigen Bedürfnissen dieser Gesundheitssysteme gerecht zu werden.
CorMedix und WSI PBG engagieren sich dafür, die Gesundheitsergebnisse zu verbessern, indem sie den Zugang zu DefenCath für Patienten in VA- und anderen Bundesbehörden erhöhen. Joe Todisco, CEO von CorMedix, äußerte sich begeistert über die Zusammenarbeit und nannte das tiefgehende Verständnis von WSI PBG für die bundesstaatliche Gesundheitslandschaft als einen Schlüsselfaktor zur Verbesserung des Zugangs zu DefenCath und zur Sicherstellung einer gerechten Versorgung für Veteranen und andere Empfänger staatlicher Gesundheitsleistungen.
- Collaboration with WSI PBG to promote DefenCath to VA and federal facilities.
- Enhanced access to critical therapies for approximately 40,000 veterans with ESRD.
- Leveraging WSI PBG's expertise in VA and federal healthcare systems.
- None.
Insights
This strategic collaboration marks a pivotal expansion into the federal healthcare market for DefenCath. The VA system represents a significant untapped market with approximately 40,000 veterans with ESRD. The partnership with WSI PBG is particularly strategic as federal healthcare facilities often have complex procurement processes that require specialized expertise to navigate effectively.
The VA market alone could represent a substantial revenue opportunity. With ESRD patients typically requiring regular dialysis treatments and considering DefenCath's potential use in preventing catheter-related bloodstream infections, this could translate to a meaningful recurring revenue stream. WSI PBG's established relationships and understanding of federal procurement processes could significantly accelerate DefenCath's adoption rate within these systems, potentially reducing the typical 12-18 month sales cycle in federal institutions.
For investors, this represents a calculated move to penetrate a reliable, government-backed market segment. Federal contracts typically offer stable, long-term revenue potential with predictable payment terms - a valuable characteristic for a commercial-stage biotech company. The collaboration also provides CorMedix with a cost-effective way to access this market without building an internal federal sales infrastructure.
The timing of this collaboration aligns well with current federal healthcare priorities focusing on preventive care and infection control in high-risk populations. The VA system's mandate to provide comprehensive care to veterans makes DefenCath's infection prevention capabilities particularly relevant, especially given the higher infection risks in dialysis patients.
The partnership with WSI PBG, a subsidiary of Golden State Medical Supply, is particularly noteworthy as they have established distribution channels and compliance frameworks within federal healthcare systems. This relationship could potentially expedite DefenCath's inclusion in federal formularies and streamline the procurement process. The federal market's emphasis on evidence-based medicine and cost-effectiveness in procurement decisions suggests that DefenCath's clinical data will be important in securing substantial market share.
BERKELEY HEIGHTS, N.J., Jan. 21, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces it has engaged with WSI PBG, a subsidiary of Golden State Medical Supply, to promote DefenCath® to healthcare providers in facilities operated by the Department of Veterans Affairs (VA) and other federal facilities. This collaboration aims to enhance access to critical therapies for the estimated 40,000 veterans living with end-stage renal disease (ESRD) and other beneficiaries of federal programs.
This engagement leverages WSI PBG's proven expertise in navigating the VA and other federal facilities, including access, procurement processes, and regulations, to meet the unique needs of federal healthcare systems. With a shared commitment to improving health outcomes, CorMedix and WSI PBG will work together to provide patients at the VA and other federal facilities with increased access to DefenCath.
Joe Todisco, CorMedix CEO, commented, “We are excited to announce our collaboration with such an established and successful government sales organization fully dedicated to the VA and federal facilities. Their deep understanding of the federal healthcare landscape will help us increase access to DefenCath and ensure equitable care for our country’s veterans and others who benefit from the federal healthcare system.”
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in adult Total Parenteral Nutrition (TPN) patients and pediatric hemodialysis (HD) patient populations in 2025 and also intends to develop DefenCath as a catheter lock solution for use in other therapeutic areas. For more information visit: www.cormedix.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to risks and uncertainties. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “will,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions or variations intended to identify forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects should be considered forward-looking statements. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, and readers are directed to the Risk Factors identified in CorMedix’s filings with the SEC, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and such forward-looking statements speak only as of the date of this press release. Investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
What is the collaboration between CorMedix and WSI PBG about?
How many veterans will benefit from the CorMedix collaboration?
What expertise does WSI PBG bring to the CorMedix collaboration?
What is the goal of the CorMedix and WSI PBG partnership?
What does the CorMedix collaboration mean for shareholders?
